Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

560.93
+2.410.43%
Post-market: 554.44-6.4900-1.16%19:04 EDT
Volume:1.14M
Turnover:640.59M
Market Cap:60.58B
PE:14.23
High:568.13
Open:561.79
Low:556.36
Close:558.52
Loading ...

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-04-21

Reuters
·
21 Apr

Regeneron's FDA Setback on Eylea HD Dosing 'No Biggie,' Says Oppenheimer

MT Newswires Live
·
21 Apr

Regeneron CRL for Eylea extension not surprising, says Oppenheimer

TIPRANKS
·
21 Apr

Regeneron receives complete response letter for Eylea extended dosing

TIPRANKS
·
21 Apr

Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria

Zacks
·
21 Apr

Sector Update: Health Care

MT Newswires Live
·
21 Apr

Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Surgery Partners (SGRY)

TIPRANKS
·
21 Apr

FDA Approves Dupixent for Chronic Hives in Patients Unresponsive to Antihistamines

MT Newswires Live
·
21 Apr

Regeneron Pharmaceuticals Says FDA Rejects Bid for Extended Eye Drug Dosing Intervals

MT Newswires Live
·
21 Apr

Regeneron announces FDA accepted Priority Review sBLA for EYLEA HD

TipRanks
·
19 Apr

Regeneron to Reassess Strategy for Retinal Condition Treatment After FDA Rejects Dosing Plan

Dow Jones
·
19 Apr

Regeneron Provides Update on Eylea Hd® (Aflibercept) Injection 8 Mg Supplemental Biologics License Application

THOMSON REUTERS
·
19 Apr

Regeneron Pharmaceuticals Inc - Crl Does Not Identify Safety or Efficacy Issues With Eylea Hd

THOMSON REUTERS
·
19 Apr

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

GlobeNewswire
·
19 Apr

BRIEF-Dupixent Approved In US As First New Targeted Therapy In Over Decade For Chronic Spontaneous Urticaria

Reuters
·
19 Apr

Regeneron, Sanofi Get FDA Approval For Dupixent in Skin Disease CSU

Dow Jones
·
18 Apr

Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition

Reuters
·
18 Apr

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

GlobeNewswire
·
18 Apr

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

GlobeNewswire
·
18 Apr

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
18 Apr